NCT03189433View on ClinicalTrials.gov

Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 12, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Drug Toxicity Psychotropic Agents Psychostimulants
Interventions
DRUG

Ryanodex (dantrolene sodium) for injectable suspension

Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.

Trial Locations (1)

21215

CrowdRx Medical Office- Moonrise Festival, Baltimore

Sponsors
All Listed Sponsors
lead

Eagle Pharmaceuticals, Inc.

INDUSTRY

NCT03189433 - Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT) | Biotech Hunter | Biotech Hunter